ConquerX is developing the next-generation medical device for molecular diagnostics, the Metachip. ConquerX's Metachip technology represents a game-changing approach to cancer diagnostics and screening by leveraging a new class of biomarkers - microRNAs - to earlier detect up to eighteen types of cancer in one simple, accurate, cost-effective blood test.
Looking for a particular ConquerX employee's phone or email?
The ConquerX annual revenue was $5 million in 2026.
ConquerX is based in Boston, Massachusetts.
The NAICS codes for ConquerX are [62, 621].
The SIC codes for ConquerX are [80, 807, 8071].